SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-256988"
 

Search: onr:"swepub:oai:DiVA.org:uu-256988" > Changes in Renal Fu...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial

Boehm, Michael (author)
Ezekowitz, Michael D. (author)
Connolly, Stuart J. (author)
show more...
Eikelboom, John W. (author)
Hohnloser, Stefan H. (author)
Reilly, Paul A. (author)
Schumacher, Helmut (author)
Brueckmann, Martina (author)
Schirmer, Stephan H. (author)
Kratz, Mario T. (author)
Yusuf, Salim (author)
Diener, Hans-Christoph (author)
Hijazi, Ziad (author)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
Wallentin, Lars (author)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
show less...
 (creator_code:org_t)
Elsevier BV, 2015
2015
English.
In: Journal of the American College of Cardiology. - : Elsevier BV. - 0735-1097 .- 1558-3597. ; 65:23, s. 2481-2493
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BACKGROUND Vitamin K-dependent factors protect against vascular and renovascular calcification, and vitamin K antagonists may be associated with a decreased glomerular filtration rate (GFR). OBJECTIVES This study analyzed changes in GFR during long-term treatment with warfarin or dabigatran etexilate (DE) in patients enrolled in the RE-LY (Randomized Evaluation of Long Term Anticoagulation Therapy) trial. METHODS Of the 18,113 patients in the RE-LY study randomized to receive DE (110 mg or 150 mg twice daily) or warfarin, 16,490 patients with atrial fibrillation had creatinine values measured at baseline and at least 1 follow-up visit. Changes in GFR for up to 30 months were evaluated. RESULTS GFR declined in all treatment groups. After an average of 30 months, the mean +/- SE decline in GFR was significantly greater with warfarin (-3.68 +/- 0.24 ml/min) compared with DE 110 mg (-2.57 +/- 0.24 ml/min; p = 0.0009 vs. warfarin) and DE 150 mg (-2.46 +/- 0.23 ml/min; p = 0.0002 vs. warfarin). A decrease in GFR >25% was less likely with DE 110 mg (hazard ratio: 0.81 [95% confidence interval: 0.69 to 0.96]; p = 0.017) or DE 150 mg (hazard ratio: 0.79 [95% confidence interval: 0.68 to 0.93]; p = 0.0056) than with warfarin in the observation period >18 months. Patients with poor international normalized ratio control (i.e., time in therapeutic range <65%) exhibited a faster decline in GFR. A more pronounced decline in GFR was associated with previous warfarin use and with the presence of diabetes. CONCLUSIONS Patients with atrial fibrillation receiving oral anticoagulation exhibited a decline in renal function that was greater in those taking warfarin versus DE, and it was amplified by diabetes and previous vitamin K antagonist use.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Keyword

anticoagulation
atrial fibrillation
renal function
thrombin inhibition
vitamin K antagonist

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view